Biotech · Private company · Orlando, FL, US
Hesperos, Inc
SEC CIK 0001907702
Track this companyFree. Adds Hesperos, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards6
- Expanded implementation of a human-based Malaria-on-a-Chip phenotypic disease model for the evaluation of therapeutic efficacy and off-target toxicityFiscal year 2026 · $1MNIH RePORTER 1R44AI197758-01 · fetched Nov 12, 2026
- Human Neuromuscular Junction Platform to Evaluate Botulinum Toxin PotencyFiscal year 2026 · $720.9KNIH RePORTER 2R44TR004811-03 · fetched Nov 12, 2026
- Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced DementiaFiscal year 2026 · $1.5MNIH RePORTER 5R44AG071386-04 · fetched Nov 12, 2026
- Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced DementiaFiscal year 2025 · $1.5MNIH RePORTER 2R44AG071386-03A1 · fetched Nov 12, 2026
- Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin PotencyFiscal year 2025 · $1MNIH RePORTER 5U44TR004811-02 · fetched Nov 12, 2026
- Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin PotencyFiscal year 2024 · $1MNIH RePORTER 1U44TR004811-01A1 · fetched Nov 12, 2026